ABOUT THIS STUDY
- Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies for monotherapy cohort.
- Patients with AML or High-Risk MDS who are newly diagnosed and previously untreated for combination cohort.
- Patients with AML who are newly diagnosed and previously untreated for azacitidine combination cohort.
- ECOG [Eastern Cooperative Oncology Group] performance status 0 to 2
- Adequate organ function
- Patients with active CNS disease
- Patient with active malignancy with the exception of basal cell carcinoma, non
melanoma skin cancer, carcinoma in situ cervical
- Patient has an active, life threatening or clinically significant uncontrolled
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- München, Bayern
- Essen, NRW
- Frankfurt am Main,
- Ann Arbor, Michigan
- Omaha, Nebraska
- Chicago, Illinois
- Indianapolis, Indiana
- Hershey, Pennsylvania